BeOne Medicines

BeOne Medicines, founded in 2010, is a global biotechnology firm specializing in oncology and clinical-stage biopharmaceutical development. The company focuses on creating innovative cancer treatments with a commitment to global accessibility and affordability. With a robust pipeline of science-driven therapies, BeOne Medicines operates at the intersection of research and commercial-stage drug delivery. Meet BeOne Medicines's team to understand the leadership driving these advancements in life science.

The organization maintains a significant operational footprint, employing over 10,000 employees across 30 global locations. This scale supports extensive R&D and clinical supply chains necessary for delivering novel molecules to patients worldwide. Learn about BeOne Medicines's global headquarters for detailed information regarding their strategic presence in Basel, Switzerland, and their broader international infrastructure.

BeOne Medicines has demonstrated strong market performance, reporting annual revenue of $5.7B. The company’s growth is bolstered by strategic partnerships and significant capital infusions, including major investments from firms like Amgen and Hillhouse Capital. Explore financial highlights to review the company's fiscal trajectory, stock issuance history, and ongoing investment in therapeutic discovery. This financial stability enables the firm to maintain its competitive edge in the global biopharmaceutical market.